In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

EJNMMI Research

Table 4 Comparison CKK2R and SSTR targeted uptake

Patient	Visible tumor uptake		CCK2R dosimetry (Gy/GBq)		SSTR2R PET/CT		Indication for PRRT
Patient	CCK2R	SST2R	w/o	w	SUVmax	SUVratio	CCK2R^c	SST2R
1	No	No	n.a	n.a	n.a	n.a	No	No
2	Yes	Yes	n.a	n.a	3.7	0.5	No	No
3	No	No	n.a	n.a	n.a	n.a	No	No
4	Yes	Yes	0.03	0.05	2.3	0.25	No	No
4^a	Yes	Yes	0.05	0.07	4.8	0.5
5	No	Yes	n.a	n.a	19.8^b	1.8^b	No	Yes
6	Yes	No	0.99	1.26	n.a	n.a	Yes	No
7	Yes	Yes	0.75	1.12	12.9	1.6	Yes	Yes
7^a	Yes	Yes	0.22	0.47	10.9	1.3
8	Yes	No	0.33	0.73	n.a	n.a	Yes	No

Visible tracer uptake in tumor in CCK2R scintigraphy and SPECT/CT and in SSTR targeted PET/CT. Tumor doses of [¹⁷⁷Lu]Lu-PP-F11N without (w/o) and with (w) Entresto^® and SUVmax, respectively ratios of SUVmax lesion to SUVmean liver of SST2R PET/CT
^a2^nd tumor in the same patient
^bMeasured in “hottest” tumor lesion
^cPotential indication for CCK2R PRRT based on visual interpretation, since there are currently no standards for the indication of CCK2R PRRT